LINCOCIN CAPSULE

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

LINCOMYCIN (LINCOMYCIN HYDROCHLORIDE)

Pieejams no:

PFIZER CANADA ULC

ATĶ kods:

J01FF02

SNN (starptautisko nepatentēto nosaukumu):

LINCOMYCIN

Deva:

500MG

Zāļu forma:

CAPSULE

Kompozīcija:

LINCOMYCIN (LINCOMYCIN HYDROCHLORIDE) 500MG

Ievadīšanas:

ORAL

Vienības iepakojumā:

100

Receptes veids:

Prescription

Ārstniecības joma:

LINCOMYCINS

Produktu pārskats:

Active ingredient group (AIG) number: 0105826001; AHFS:

Autorizācija statuss:

CANCELLED POST MARKET

Autorizācija datums:

2006-08-02

Produkta apraksts

PRODUCT MONOGRAPH
LINCOCIN
*
LINCOMYCIN INJECTION USP
300 MG/ML STERILE SOLUTION
LINCOMYCIN HYDROCHLORIDE CAPSULES USP
500 MG CAPSULES
ANTIBIOTIC
Pfizer Canada Inc
17,300 Trans-Canada Highway
Kirkland, Quebec H9J 2M5
Date of revision:
April 8, 2008
CONTROL NUMBER: 119402
*
TM Pharmacia & Upjohn Company LLC
Pfizer Canada Inc, Licensee
©
Pfizer Canada Inc 2008
2
LINCOCIN
*
LINCOMYCIN INJECTION USP
300 MG/ML STERILE SOLUTION
LINCOMYCIN HYDROCHLORIDE CAPSULES USP
500 MG CAPSULES
THERAPEUTIC CLASSIFICATION
ANTIBIOTIC
ACTION, CLINICAL PHARMACOLOGY
The mode of action of lincomycin hydrochloride is the inhibition of
protein synthesis by the inhibition of
the binding of aminoacyl sRNA to the messenger ribosome complex at the
50S ribosomal unit.
INDICATIONS AND CLINICAL USES
LINCOCIN (lincomycin hydrochloride) is indicated in the treatment of
serious infections due to sensitive
gram positive organisms (staphylococci, including
penicillinase-producing staphylococci, streptococci
and pneumococci) when the patient is intolerant of, or the organism
resistant to other appropriate
antibiotics.
LINCOCIN is indicated in the treatment of osteomyelitis, when the
causative organism has been found to
be sensitive to this antibiotic.
CONTRAINDICATIONS
As with all drugs, the use of LINCOCIN (lincomycin hydrochloride) is
contraindicated in patients
previously found to be hypersensitive to the drug or patients who have
previously been found
hypersensitive to clindamycin (Dalacin C) or to any other component of
the product.
3
LINCOCIN should not be given to persons with known pre-existing
monilial infections.
Until further clinical experience is obtained, LINCOCIN is not
indicated in the newborn.
WARNINGS
_Clostridium difficile_
-associated disease (CDAD) has been reported with use of many
antibacterial agents,
including LINCOCIN ( lincomycin hydrochloride). CDAD may range in
severity from mild diarrhoea to
fatal colitis. It is important to consider this diagnosis in patients
who present with diarrhoea, or symptoms
of colitis, pseudomembr